JAZZ Q4 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$972M+8.4% YoY

Gross Profit

$805M82.8% margin

Operating Income

-$263M-27.1% margin

Net Income

-$240M-24.7% margin

EPS (Diluted)

$-3.81

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

$342M

Free Cash Flow

$333M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$10.8B

Total Liabilities

$7.7B

Stockholders' Equity

$3.1B

Cash & Equivalents

$881M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$972M	$897M	+8.4%
Gross Profit	$805M	$761M	+5.8%
Operating Income	-$263M	$49M	-633.4%
Net Income	-$240M	-$35M	-578.8%

Revenue Segments

Xywav

$281M29%

Xyrem

$247M26%

Epidiolex/Epidyolex

$207M21%

Rylaze/Enrylaze

$81M8%

Zepzelca

$72M7%

Defitelio/Defibrotide

$41M4%

Vyxeos

$30M3%

Sativex

$5M0%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$904M93%

Europe

$58M6%

Other Countries

$11M1%